Although research has shown that adults should sleep at least 7 hours per night, the 2014 Behavioral Risk Factor Surveillance System reported that approximately 35% of adults got insufficient sleep.
Malignant hyperthermia must be treated rapidly to avoid fatality, and despite its rarity, healthcare facilities that use known triggering agents must be fully prepared to treat it.
Scientists from the University of Eastern Finland have identified alterations occurring in the human brain that signal the early stages of this common neurogenerative disease.
The FDA’s review of drug and biological products in this medication class is critical, as a brain impairment impacts between 6.5% and 7.9% of adults in the United States.